Modulation of cancer-specific immune responses by amino acid degrading enzymes

Immunotherapy

Volumn 9, Issue 1, 2017, Pages 83-97

  Timosenko, Elina ^a   Hadjinicolaou, Andreas V ^a   Cerundolo, Vincenzo ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

arginase; immunosuppression; indoleamine 2 3 dioxygenase; tryptophan 2 3 dioxygenase; tumor microenvironment

Indexed keywords

ARGINASE; ARGININE DEGRADING ENZYME; ENZYME; INDOLEAMINE 2,3 DIOXYGENASE; PROTEIN ARG1; PROTEIN ARG2; TRYPTOPHAN 2,3 DIOXYGENASE; TRYPTOPHAN DEGRADING ENZYME; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVITY; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ARGINASE; HUMANS; IMMUNITY; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MOLECULAR TARGETED THERAPY; NEOPLASMS; TRYPTOPHAN OXYGENASE; TUMOR ESCAPE;

EID: 85007210906     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0118     Document Type: Review

References (139)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
2. Zou WP. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005).
3. Theate I, Van Baren N, Pilotte L et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol. Res. 3(2), 161-172 (2015).
4. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189(9), 1363-1372 (1999).
5. Munn DH, Sharma MD, Lee JR et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297(5588), 1867-1870 (2002).
6. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106(7), 2375-2381 (2005).
7. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3(11), 1097-1101 (2002).
8. Fallarino F, Grohmann U, Hwang KW et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4(12), 1206-1212 (2003).
9. Pilotte L, Larrieu P, Stroobant V et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl Acad. Sci. USA 109(7), 2497-2502 (2012).
10. Schmidt SV, Schultze JL. New insights into IDO biology in bacterial and viral infections. Front. Immunol. 5, 384 (2014).
11. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380), 1191-1193 (1998).
12. Yeung AW, Terentis AC, King NJ, Thomas SR. Role of indoleamine 2,3-dioxygenase in health and disease. Clin. Sci. (Lond.) 129(7), 601-672 (2015).
13. Ravishankar B, Liu HY, Shinde R et al. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl Acad. Sci. USA 109(10), 3909-3914 (2012).
14. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67(15), 7082-7087 (2007).
15. Metz R, Smith C, Duhadaway JB et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int. Immunol. 26(7), 357-367 (2014).
16. Merlo LMF, Pigott E, Duhadaway JB et al. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J. Immunol. 192(5), 2082-2090 (2014).
17. Morris SM Jr. Arginine: beyond protein. Am. J. Clin. Nutr. 83(2), s508-s512 (2006).
18. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336(Pt 1), 1-17 (1998).
19. Kim PS, Iyer RK, Lu KV et al. Expression of the liver form of arginase in erythrocytes. Mol. Genet. Metab. 76(2), 100-110 (2002).
20. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25(4), 1101-1104 (1995).
21. Mayer AK, Bartz H, Fey F, Schmidt LM, Dalpke AH. Airway epithelial cells modify immune responses by inducing an anti-inflammatory microenvironment. Eur. J. Immunol. 38(6), 1689-1699 (2008).
22. Pesce J, Kaviratne M, Ramalingam TR et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116(7), 2044-2055 (2006).
23. Boucher JL, Custot J, Vadon S et al. N omega-hydroxyl-Larginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem. Biophys. Res. Commun. 203(3), 1614-1621 (1994).
24. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J. Nutr. 137(6 Suppl 2), s1616-s1620 (2007).
25. Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, Cederbaum SD. Cloning and characterization of the human type II arginase gene. Genomics 38(2), 118-123 (1996).
26. Gotoh T, Sonoki T, Nagasaki A, Terada K, Takiguchi M, Mori M. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett. 395(2-3), 119-122 (1996).
27. Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol. Genet. Metab. 84(3), 243-251 (2005).
28. Deignan JL, Livesay JC, Yoo PK et al. Ornithine deficiency in the arginase double knockout mouse. Mol. Genet. Metab. 89(1-2), 87-96 (2006).
29. Iyer RK, Bando JM, Jenkinson CP et al. Cloning and characterization of the mouse and rat type II arginase genes. Mol. Genet. Metab. 63(3), 168-175 (1998).
30. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc. Natl Acad. Sci. USA 93(13), 6770-6774 (1996).
31. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 287(1), L60-L68 (2004).
32. Hey C, Boucher JL, Vadon-Le Goff S, Ketterer G, Wessler I, Racke K. Inhibition of arginase in rat and rabbit alveolar macrophages by N omega-hydroxy-D, L-indospicine, effects on L-arginine utilization by nitric oxide synthase. Br. J. Pharmacol. 121(3), 395-400 (1997).
33. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 163(7), 3771-3777 (1999).
34. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3(1), 23-35 (2003).
35. Fujii W, Ashihara E, Hirai H et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J. Immunol. 191(3), 1073-1081 (2013).
36. Xu L, Hilliard B, Carmody RJ et al. Arginase and autoimmune inflammation in the central nervous system. Immunology 110(1), 141-148 (2003).
37. Corraliza I, Moncada S. Increased expression of arginase II in patients with different forms of arthritis. Implications of the regulation of nitric oxide. J. Rheumatol. 29(11), 2261-2265 (2002).
38. Wu H, Zhen Y, Ma Z et al. Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci. Transl. Med. 8(331), 331ra340 (2016).
39. Chakravortty D, Hensel M. Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect 5(7), 621-627 (2003).
40. Das P, Lahiri A, Lahiri A, Chakravortty D. Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. PLoS Pathog. 6(6), e1000899 (2010).
41. Munder M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 158(3), 638-651 (2009).
42. Munder M, Schneider H, Luckner C et al. Suppression of T-cell functions by human granulocyte arginase. Blood 108(5), 1627-1634 (2006).
43. Kropf P, Baud D, Marshall SE et al. Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur. J. Immunol. 37(4), 935-945 (2007).
44. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 277(24), 21123-21129 (2002).
45. Taheri F, Ochoa JB, Faghiri Z et al. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin. Cancer. Res. 7(Suppl. 3), s958-s965 (2001).
46. Fallarino F, Grohmann U, You S et al. The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176(11), 6752-6761 (2006).
47. Elahi S, Ertelt JM, Kinder JM et al. Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature 504(7478), 158-162 (2013).
48. Edinger AL, Thompson CB. Antigen-presenting cells control T cell proliferation by regulating amino acid availability. Proc. Natl Acad. Sci. USA 99(3), 1107-1109 (2002).
49. Dunand-Sauthier I, Irla M, Carnesecchi S et al. Repression of arginase-2 expression in dendritic cells by microRNA-155 is critical for promoting T cell proliferation. J. Immunol. 193(4), 1690-1700 (2014).
50. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9(10), 1269-1274 (2003).
51. Opitz CA, Litzenburger UM, Sahm F et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368), 197-203 (2011).
52. Lob S, Konigsrainer A, Zieker D et al. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immun. 58(1), 153-157 (2009).
53. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114(2), 280-290 (2004).
54. Sharma MD, Baban B, Chandler P et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117(9), 2570-2582 (2007).
55. Ling WF, Zhang JM, Yuan ZR et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res. 74(5), 1576-1587 (2014).
56. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin. Cancer. Res. 17(22), 6985-6991 (2011).
57. Folgiero V, Goffredo BM, Filippini P et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 5(8), 2052-2064 (2014).
58. Muller AJ, Duhadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11(3), 312-319 (2005).
59. Balachandran VP, Cavnar MJ, Zeng S et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17(9), U1094-U1099 (2011).
60. Basu GD, Tinder TL, Bradley JM et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177(4), 2391-2402 (2006).
61. Von Bergwelt-Baildon MS, Popov A, Saric T et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108(1), 228-237 (2006).
62. Spranger S, Spaapen RM, Zha Y et al. Up-regulation of PD-L1, IDO, and T-regs in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5(200), 200ra116 (2013).
63. Silk JD, Lakhal S, Laynes R et al. IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells. J. Immunol. 187(4), 1617-1625 (2011).
64. Kudo Y, Boyd CAR, Sargent IL, Redman CWG. Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation. J. Physiol. 535(1), 207-215 (2001).
65. Munn DH, Sharma MD, Baban B et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22(5), 633-642 (2005).
66. Fallarino I, Grohmann U, Vacca C et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9(10), 1069-1077 (2002).
67. Lee SM, Lee YS, Choi JH et al. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Immunol. Lett. 132(1-2), 53-60 (2010).
68. Iken K, Liu KF, Liu HZ et al. Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells. Am. J. Respir. Cell Mol. Biol. 47(4), 405-416 (2012).
69. Eleftheriadis T, Pissas G, Antoniadi G, Spanoulis A, Liakopoulos V, Stefanidis I. Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. Int. Immunol. 26(12), 673-684 (2014).
70. Timosenko E, Ghadbane H, Silk JD et al. Nutritional stress induced by tryptophan-degrading enzymes results in ATF4-dependent reprogramming of the amino acid transporter profile in tumor cells. Cancer Res. 76(21), 6193-6204 (2016).
71. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181(8), 5396-5404 (2008).
72. Curti A, Pandolfi S, Valzasina B et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25(-) into CD25(+) T regulatory cells. Blood 109(7), 2871-2877 (2007).
73. Liu XQ, Lu K, Feng LL et al. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration. Leuk. Lymphoma 55(2), 405-414 (2014).
74. Curti A, Trabanelli S, Onofri C et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 95(12), 2022-2030 (2010).
75. Cobbold SP, Adams E, Farquhar CA et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl Acad. Sci. USA 106(29), 12055-12060 (2009).
76. Mezrich JD, Fechner JH, Zhang XJ, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185(6), 3190-3198 (2010).
77. Sharma MD, Hou DY, Liu YJ et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3(+) Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113(24), 6102-6111 (2009).
78. Pallotta MT, Orabona C, Volpi C et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12(9), U870-U891 (2011).
79. Volpi C, Mondanelli G, Pallotta MT et al. Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells. Neuropharmacology 102, 59-71 (2016).
80. Holmgaard RB, Zamarin D, Li YY et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13(2), 412-424 (2015).
81. Romani L, Fallarino F, De Luca A et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451(7175), U211-U212 (2008).
82. Molano A, Illarionov PA, Besra GS, Putterman C, Porcelli SA. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol. Lett. 117(1), 81-90 (2008).
83. Wang XF, Wang HS, Wang H et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell. Immunol. 289(1-2), 42-48 (2014).
84. Pietra G, Manzini C, Rivara S et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 72(6), 1407-1415 (2012).
85. Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. J. Exp. Ther. Oncol. 3(6), 336-345 (2003).
86. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 61(3), 1100-1106 (2001).
87. Gannon PO, Godin-Ethier J, Hassler M et al. Androgenregulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS ONE 5(8), e12107 (2010).
88. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 60(12), 3305-3312 (2000).
89. Suer Gokmen S, Yoruk Y, Cakir E, Yorulmaz F, Gulen S. Arginase and ornithine, as markers in human non-small-cell lung carcinoma. Cancer Biochem. Biophys. 17(1-2), 125-131 (1999).
90. Tate DJ Jr, Vonderhaar DJ, Caldas YA et al. Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma. J. Hematol. Oncol. 1, 14 (2008).
91. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap? Mol. Genet. Metab. 81(Suppl. 1), S38-S44 (2004).
92. Bronte V, Kasic T, Gri G et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201(8), 1257-1268 (2005).
93. Wu CW, Chi CW, Tsay SH et al. The effects of arginase on neoplasm. I. The role of arginase in the immunosuppressive effects of extract from gastric cancer. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 20(4), 279-289 (1987).
94. Wu CW, Chi CW, Lin EC, Lui WY, P'eng FK, Wang SR. Serum arginase level in patients with gastric cancer. J. Clin. Gastroenterol. 18(1), 84-85 (1994).
95. Porembska Z, Luboinski G, Chrzanowska A, Mielczarek M, Magnuska J, Baranczyk-Kuzma A. Arginase in patients with breast cancer. Clin. Chim. Acta 328(1-2), 105-111 (2003).
96. Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat. Rev. Drug Discov. 14(9), 603-622 (2015).
97. Bronte V, Apolloni E, Cabrelle A et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96(12), 3838-3846 (2000).
98. Bronte V, Serafini P, De Santo C et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170(1), 270-278 (2003).
99. Gabrilovich Di, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166(9), 5398-5406 (2001).
100. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich Di. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172(2), 989-999 (2004).
101. Mazzoni A, Bronte V, Visintin A et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168(2), 689-695 (2002).
102. Vasquez-Dunddel D, Pan F, Zeng Q et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 123(4), 1580-1589 (2013).
103. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J. Immunol. 166(4), 2173-2177 (2001).
104. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigenspecific T-cell responses. Cancer Res. 64(16), 5839-5849 (2004).
105. Bak SP, Alonso A, Turk MJ, Berwin B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol. Immunol. 46(2), 258-268 (2008).
106. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloidderived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68(13), 5439-5449 (2008).
107. Rodriguez PC, Ernstoff MS, Hernandez C et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69(4), 1553-1560 (2009).
108. De Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology 1(8), 1305-1312 (2012).
109. Jacobsen LC, Theilgaard-Monch K, Christensen EI, Borregaard N. Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils. Blood 109(7), 3084-3087 (2007).
110. Zea AH, Rodriguez PC, Atkins MB et al. Arginaseproducing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65(8), 3044-3048 (2005).
111. Mussai F, De Santo C, Abu-Dayyeh I et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122(5), 749-758 (2013).
112. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3), 211-217 (2005).
113. Pucci F, Venneri MA, Biziato D et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114(4), 901-914 (2009).
114. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int. J. Oncol. 17(3), 445-451 (2000).
115. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer. Res. 13(2 Pt 2), 721s-726s (2007).
116. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM. Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethaneinduced primary lung tumorigenesis in A/J mice. Am. J. Pathol. 170(2), 693-708 (2007).
117. Ino Y, Yamazaki-Itoh R, Oguro S et al. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS ONE 8(2), e55146 (2013).
118. Hou DY, Muller AJ, Sharma MD et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67(2), 792-801 (2007).
119. Koblish HK, Hansbury MJ, Bowman KJ et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol. Cancer Ther. 9(2), 489-498 (2010).
120. Li M, Bolduc AR, Hoda MN et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J. Immunother. Cancer 2, 21 (2014).
121. Sugimoto H, Oda SI, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O-2 incorporation by a hemecontaining dioxygenase. Proc. Natl Acad. Sci. USA 103(8), 2611-2616 (2006).
122. Mellor AL, Baban B, Chandler P et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171(4), 1652-1655 (2003).
123. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210(7), 1389-1402 (2013).
124. Soliman HH, Jackson E, Neuger T et al. A first in man Phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5(18), 8136-8146 (2014).
125. Zakharia Y, Drabick J, Khleif S et al. Results of Phase 1b trial of the indoleamine 2,3-dioxygenase (IDO) pathway inhibitor indoximod plus ipilimumab for the treatment of unresectable stage III or IV melanoma. Eur. J. Cancer 51, S108-S108 (2015).
126. Soliman HH, Minton SE, Ismail-Khan R et al. A Phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer. Cancer Res. doi:10.1158/1538-7445.SABCS14-P2-15-04 75(9), (2015).
127. Gibney G, Hamid O, Lutzky J et al. Updated results from a Phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. Eur. J. Cancer 51, S106-S107 (2015).
128. Lee SY, Choi HK, Lee KJ et al. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother. 32(1), 22-28 (2009).
129. Iachininoto MG, Nuzzolo ER, Bonanno G et al. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells. Molecules 18(9), 10132-10145 (2013).
130. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J. Pharm. Pharm. Sci. 7(3), 332-336 (2004).
131. Andersen MH. Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J. Natl Cancer Inst. doi:10.1093/jnci/djv154 107(9), (2015).
132. Iversen TZ, Engell-Noerregaard L, Ellebaek E et al. Longlasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin. Cancer Res. 20(1), 221-232 (2014).
133. Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, Svane IM. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy 18(8), 1043-1055 (2016).
134. Rodriguez PC, Ochoa AC. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin. Cancer Biol. 16(1), 66-72 (2006).
135. Works M, Bennett M, Chen JJ et al. Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response. Presented at: AACR 107th Annual Meeting. New Orleans, LA, USA, 16-20 April 2016.
136. Crittenden MR, Savage T, Cottam B et al. Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice. Radiat. Res. 182(2), 182-190 (2014).
137. Gupta S, Ahmad N, Marengo SR, Maclennan GT, Greenberg NM, Mukhtar H. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res. 60(18), 5125-5133 (2000).
138. Serafini P, Meckel K, Kelso M et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203(12), 2691-2702 (2006).
139. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6(9), 714-727 (2006).